Gastric Cancer Clinical Trial
Official title:
A Real World Study of the Effect of Laparoscopic Preservation of the Pylorus and Vagus Nerve on the Postoperative Quality of Life in Patients With Early Gastric Cancer
For the patients with early gastric cancer (T1), preoperative evaluation (gastroscope, ultrasound gastroscope and abdominal enhanced CT) showed that the tumor was located in the body of the stomach, and the margin was enough to retain the pylorus and non lymph node metastasis (N0). Lappg (D1 + lymph node dissection) and traditional laparoscopic distal gastrectomy (BII type anastomosis, D1 + lymph node dissection) were included A control study was conducted to evaluate the difference of long-term quality of life, gastric emptying rate, incidence of basic reflux gastritis, bile contraction function, immune index, nutritional index and disease-free survival and overall survival between the two groups.
The overall design of this study is an experimental study based on the real world. All the
patients in the study group were from early gastric cancer patients who were operated on in
gastrointestinal surgery of Renji Hospital. According to the preoperative evaluation of early
gastric cancer (gastroscope, ultrasonic gastroscope and abdominal enhanced CT), patients with
early gastric cancer whose tumor is located in the gastric body and whose cutting edge is
enough to retain pylorus and non lymph node metastasis (N0) were included in the study. Group
A (Study Group): lappg treatment group, group B (control group): laparoscopic distal
gastrectomy type I group. In this study, group A was taken as the study group and group B as
the control group Group, the differences between groups were compared. The main end point was
the quality of life score (eortc-qlq-c30 scale, see the attached table). According to the
literature and the data of the retrospective study of the center, it was assumed that the
expected mean of the study group after treatment was 7.27, the mean of the control group
after treatment was 6.76, and the total standard deviation of the test group and the control
group was 0.51. The design of the test group and the control group was 1:1. According to
this, two independent α = 0.05 were carried out Test of the average number of standing
samples. It is calculated that 144 patients (72 in each group) are needed, so that under the
test level of α = 0.05, according to 80% test efficiency, the difference between the two
groups is statistically significant. Assuming that 10% of the patients could not be evaluated
(shedding), 80 patients in each group were enrolled, and 160 patients in both groups were
enrolled.
2) inclusion / exclusion / withdrawal criteria of subjects
Inclusion criteria: 18 years old < age < 75 years old; primary gastric lesions were diagnosed
as gastric adenocarcinoma by tissue biopsy; preoperative clinical stage was T1N0M0 according
to ajcc-7thtnm tumor stage; the tumor site was expected to receive R0 after pylorus
preserving gastrectomy and D1 + lymph node dissection; preoperative Eastern Cooperative
Oncology Group physical state score was 0 / 1; preoperative ASA score was I-III, with
informed consent of the patient.
Exclusion criteria: pregnant or lactating women; severe mental illness; history of upper
abdominal surgery (except for laparoscopic cholecystectomy); history of gastric surgery
(including endoscopic submucosal dissection/ endoscopic mucosal resection for gastric
cancer); preoperative imaging examination showed regional enlarged lymph nodes; history of
other malignant diseases within 5 years; patients with gastric cancer who have implemented
new adjuvant treatment or recommended new adjuvant treatment; no History of stable angina
pectoris or myocardial infarction; history of cerebral infarction or cerebral hemorrhage
within 6 months; history of continuous systemic corticosteroid therapy within 1 month;
simultaneous operation for other diseases; emergency operation for gastric cancer with
complications (hemorrhage, perforation, obstruction).
Withdrawal criteria: conversion to laparotomy; intraoperative / postoperative pathological
confirmation of tumor invasion depth exceeding T1, or tumor invasion of duodenum;
intraoperative / postoperative pathological confirmation of lymph node metastasis;
intraoperative / postoperative pathological confirmation of M1 cases; intraoperative
confirmation of failure to complete D1 + lymph node dissection / R0 due to tumor reasons;
intraoperative confirmation of the need for total gastrectomy to ensure safe proximity; need
for other diseases During the same period of the study, the patients were operated at the
same time; because of severe complications (unable to tolerate surgery or anesthesia) during
the perioperative period, the treatment plan of the study was not suitable or could not be
implemented according to the plan; after entering the study, because of the patient's
condition change, the emergency operation was confirmed by the doctor in charge; at any stage
after entering the study, the patients voluntarily requested to withdraw or suspend the
treatment due to the patient's personal reasons Treatment; treatment proven to be in
violation of this protocol.
3) end point of study
Primary endpoint: 5-year quality of life assessment [time window: 5 years after operation].
Secondary endpoint: 3-year quality of life [time window: 3 years after operation]; immune
index [time window: 5 years after operation]; nutritional index [time window: 5 years after
operation]; gastric emptying rate [time window: 5 years after operation]; incidence of basic
reflux gastritis [time window: 5 years after operation]; gallbladder contraction function
[time window: 5 years after operation]; 5-year total survival rate [time window: 5 years
after operation] 5 years; 5-year recurrence free survival [time window: 5 years after
operation].
4) diagnostic criteria for this study
In this study, ajcc-7th primary tumor, regional nodes, metastasis tumor staging system was
used; the diagnostic criteria and classification of gastric cancer were based on the
international diagnostic criteria of histopathology; the definition of early gastric cancer:
tumor infiltration was limited to the mucosa and submucosa, and did not invade the muscular
layer (T1); in this study, T1N0 was the study object, but not the study object.
5) interventions
According to the preoperative evaluation (gastroscope, ultrasonic gastroscope and abdominal
enhanced CT), the tumor is located in the body of the stomach, and the cutting edge is enough
to retain the pylorus and early gastric cancer without lymph node metastasis (N0). By
randomized grouping, the laparoscopic pylorus preserving gastrectomy (lappg, D1 +
lymphadenectomy) and traditional laparoscopic distal gastrectomy (BII type anastomosis, D1 +
lymphadenectomy) are performed Bed operation intervention.
6) statistical analysis
In demographic indicators, numerical variables are mainly described by means of means and
standard deviations, and classified variables are mainly described by rates or ratios.
T-test, chi square test or nonparametric test can be used to test the equilibrium of two
groups of demography.
Statistical analysis method of main index and secondary index. The main index is patients'
postoperative quality of life score (postscript symptom scores), which is a numerical
variable. The statistical description mainly uses mean and standard deviation. Statistical
inference uses t-test, ANOVA or nonparametric test according to data distribution conditions.
The secondary indicators involve the expression of usage rate of classified statistical
description, and the expression of chi square test of statistical inference hypothesis test.
If there is no balance between the two groups, we can use multiple regression to adjust the
confounding factors and compare the difference between the two groups.
;
Status | Clinical Trial | Phase | |
---|---|---|---|
Recruiting |
NCT05551416 -
The EpiGASTRIC/EDGAR Project: New Strategies for the Early Detection and Prevention of Gastric Cancer
|
||
Completed |
NCT05518929 -
Hypoxia During Gastroenterological Endoscope Procedures Sedated With Ciprofol In Overweight Or Obesity Patients
|
Phase 4 | |
Recruiting |
NCT06006390 -
CEA Targeting Chimeric Antigen Receptor T Lymphocytes (CAR-T) in the Treatment of CEA Positive Advanced Solid Tumors
|
Phase 1/Phase 2 | |
Recruiting |
NCT03219593 -
Apatinib as the First-Line Therapy in Elderly Locally Advanced or Metastatic Gastric Cancer
|
Phase 2 | |
Recruiting |
NCT05489211 -
Study of Dato-Dxd as Monotherapy and in Combination With Anti-cancer Agents in Patients With Advanced Solid Tumours (TROPION-PanTumor03)
|
Phase 2 | |
Recruiting |
NCT05536102 -
The Effectiveness and Safety of XELOX and Tislelizumab + PLD for Resectable Gastric Cancer (LidingStudy)
|
Phase 2 | |
Active, not recruiting |
NCT03170960 -
Study of Cabozantinib in Combination With Atezolizumab to Subjects With Locally Advanced or Metastatic Solid Tumors
|
Phase 1/Phase 2 | |
Recruiting |
NCT06010862 -
Clinical Study of CEA-targeted CAR-T Therapy for CEA-positive Advanced/Metastatic Malignant Solid Tumors
|
Phase 1 | |
Recruiting |
NCT05415098 -
Study of Safety, Pharmacokinetic and Efficacy of APG-5918 in Advanced Solid Tumors or Lymphomas
|
Phase 1 | |
Active, not recruiting |
NCT04082364 -
Combination Margetuximab, Retifanlimab, Tebotelimab, and Chemotherapy Phase 2/3 Trial in HER2+ Gastric/GEJ Cancer
|
Phase 2/Phase 3 | |
Withdrawn |
NCT03766607 -
Trastuzumab Beyond Progression in HER2 Positive Metastatic Gastric Cancer
|
Phase 2 | |
Recruiting |
NCT04118114 -
Phase II Study of PRL3-ZUMAB in Advanced Solid Tumors
|
Phase 2 | |
Completed |
NCT01924533 -
Efficacy and Safety Study of Olaparib in Combination With Paclitaxel to Treat Advanced Gastric Cancer.
|
Phase 3 | |
Terminated |
NCT01641939 -
A Study of Trastuzumab Emtansine Versus Taxane in Participants With Human Epidermal Growth Factor Receptor 2 (HER2)-Positive Advanced Gastric Cancer
|
Phase 2/Phase 3 | |
Recruiting |
NCT05107674 -
A Study of NX-1607 in Adults With Advanced Malignancies
|
Phase 1 | |
Active, not recruiting |
NCT04908813 -
Study of HLX22 in Combanition With Trastuzumab and Chemotherapy Versus Placebo in Combination With Trastuzumab and Chemotherapy for Treatment of Locally Advanced or Metastatic Gastric Cancer
|
Phase 2 | |
Active, not recruiting |
NCT04249739 -
Pembrolizumab + Capecitabine/Oxaliplatin (CapeOx) -HER2 Nagative and Pembrolizumab + Trastuzumab + Cisplatin/Capecitabine HER2 Positive
|
Phase 2 | |
Recruiting |
NCT05514158 -
To Evaluate the Safety, Tolerability, Pharmacokinetics and Preliminary Efficacy of Disitamab Vedotin Combined With RC98 in the Treatment of Subjects With HER2-expressing Locally Advanced or Metastatic Gastric Cancer (Including AEG)
|
Phase 1 | |
Recruiting |
NCT04931654 -
A Study to Assess the Safety and Efficacy of AZD7789 in Participants With Advanced or Metastatic Solid Cancer
|
Phase 1/Phase 2 | |
Recruiting |
NCT03175224 -
APL-101 Study of Subjects With NSCLC With c-Met EXON 14 Skip Mutations and c-Met Dysregulation Advanced Solid Tumors
|
Phase 2 |